Exenatide and the treatment of patients with Parkinson's disease
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
UNLABELLED: BACKGROUND. There is increasing interest in methods to more rapidly and cost-efficiently investigate drugs that are approved for clinical use in the treatment of another condition. Exenatide is a type 2 diabetes treatment that has been shown to have neuroprotective/neurorestorative properties in preclinical models of neurodegeneration. METHODS. As a proof of concept, using a single-blind trial design, we evaluated the progress of 45 patients with moderate Parkinson's disease (PD), randomly assigned to receive subcutaneous exenatide injection for 12 months or to act as controls. Their PD was compared after overnight withdrawal of conventional PD medication using blinded video assessment of the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS), together with several nonmotor tests, at baseline, 6 months, and 12 months and after a further 2-month washout period (14 months). RESULTS. Exenatide was well tolerated, although weight loss was common and l-dopa dose failures occurred in a single patient. Single-blinded rating of the exenatide group suggested clinically relevant improvements in PD across motor and cognitive measures compared with the control group. Exenatide-treated patients had a mean improvement at 12 months on the MDS-UPDRS of 2.7 points, compared with mean decline of 2.2 points in control patients (P = 0.037). CONCLUSION. These results demonstrate a potential cost-efficient approach through which preliminary clinical data of possible biological effects are obtainable, prior to undertaking the major investment required for double-blind trials of a potential disease-modifying drug in PD. TRIAL REGISTRATION: Clinicaltrials.gov NCT01174810. FUNDING: Cure Parkinson's Trust.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Three clinical trials consistently describe a slowed decline in motor function when using the short-acting GLP-1 receptor agonists exenatide and lixisenatide in people with Parkinson's disease; 102-104”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [103]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“According to preliminary clinical trials, patients treated with exenatide improved by 2.7 points on the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) after 12 months, compared to a decline of 2.2 points in control patients. 86”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [86]
In the citing paper
“Another single-blind, phase 2 trial evaluated exenatide, which improved motor deficits in PD patients for more than 12 months.523”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [523]
In the citing paper
“Therefore, diabetes drugs such as GLP-1 are used to treat AD and PD, and have shown good efficacy (Aviles-Olmos et al. 2013; Gejl et al. 2016).”
From Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease (2020) · cites this paper as Aviles-Olmos et al. 2013
In the citing paper
“Currently, GLP-1 drugs have been used in AD and PD patients in clinical trials and have shown efficacy (Aviles-Olmos et al. 2013; Gejl et al. 2016).”
From Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer’s disease and Parkinson’s disease (2020) · cites this paper as Aviles-Olmos et al. 2013
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 2×
“The frequency of the adverse events in the exenatide group was similar to that seen in the previous clinical trials of exenatide in diabetes patients (4, 5).”
BackgroundResultWeaver, F. M. (2009) · JAMA · doi:10.1001/jama.2008.929 · Cited by 1,525
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · cited 1×
“The first of these, exendin-4, was discovered in the saliva of the Gila monster (3) and found to have beneficial effects on glucose homeostasis through stimulation of glucose level–dependent insulin release, islet cell proliferation, reduction of islet cell apoptosis, and weight loss (4, 5).”
BackgroundGlucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589
(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561 · cited 1×
“8) (23), although this can vary Table 4 Adverse events reported by trial participants”
BackgroundThe NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453
Kolterman, O. G., Kim, D. D., Shen, L., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. D. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.2.173 · Cited by 434
Cited by
Items 201–300 of 529
Fan, Y., Liu, K., Wang, Q., Ruan, Y., Zhang, Y., & Ye, W. (2014) · PubMed Central · Cited by 56
Uenaka, T., Satake, W., Cha, P.-C., Hayakawa, H., Baba, K., Jiang, S., Kobayashi, K., Kanagawa, M., Okada, Y., Mochizuki, H., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy279 · Cited by 48
Metformin as a Potential Neuroprotective Agent in Prodromal Parkinson's Disease—Viewpoint
Sportelli, C., Urso, D., Jenner, P. G., & Chaudhuri, К. R. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00556 · Cited by 50
Alpha synuclein post translational modifications: potential targets for Parkinson’s disease therapy?
Brembati, V., Faustini, G., Longhena, F., & Bellucci, A. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1197853 · Cited by 44
Tang, H., Lu, Y., Okun, M. S., Donahoo, W. T., Ramirez‐Zamora, A., Wang, F., Huang, Y., Armstrong, M. J., Svensson, M., Virnig, B. A., et al. (2024) · Movement Disorders · doi:10.1002/mds.29992 · Cited by 47
Brundin, P., Barker, R. A., Conn, P. J., Dawson, T. M., Kieburtz, K. D., Lees, A. J., Schwarzschild, M. A., Tanner, C. M., Isaacs, T., Duffen, J., et al. (2013) · Journal of Parkinson s Disease · doi:10.3233/jpd-139000 · Cited by 43
“The recently-published Exenatide pilot clinical trial [18] apart from its clinical findings, also demonstrated the feasibility [19] of running a learning trial in a relatively small number of PD patients.”
Self-citationIs Exenatide a Treatment for Parkinson’s Disease?
Athauda, D. S., Wyse, R. K. H., Brundin, P., & Foltynie, T. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-171192 · Cited by 44
Self-citationCan Growth Factors Cure Parkinson’s Disease?
Sidorova, Y. A., & Saarma, M. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.09.010 · Cited by 45
“, an antidiabetic drug exenatide) [3].”
Drug repositioning in drug discovery of T2DM and repositioning potential of antidiabetic agents
Zhu, S., Bai, Q., Li, L., & Xu, T. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.05.057 · Cited by 46
“A meta -analysis [134] and several clinical trials [135,136] have demonstrated the therapeutic potential of exenatide in improving motor symptoms in PD patients.”
BackgroundNeuroprotective effects of GLP-1 class drugs in Parkinson’s disease
Lv, D., Feng, P., Guan, X., Liu, Z., Li, D., Xue, C., Bai, B., & Hölscher, C. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1462240 · Cited by 49
Enteroendocrine cells: the gatekeepers of microbiome-gut-brain communication
Grundeken, E., & Aidy, S. E. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00810-x · Cited by 55
“Treatedgroupsexhibitedreducedmotordisability progression 125 or evenimprovement 126,127 compared to controls.”
Qin, X., Zhang, X., Li, P., Wang, M., Li, Y., Bao, Z., & Liu, Q. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.678649 · Cited by 44
Diabetes mellitus and Parkinson’s disease: dangerous liaisons between insulin and dopamine
Colosimo, C., Iuliis, A. D., Montinaro, E., Fatati, G., & Plebani, M. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.320965 · Cited by 47
“…cohort study Long-term metformin therapy (> 2 years) was associated with a lower incidence of PD among elderly veterans with T2DM Exendin-4 Aviles-Olmos et al., 2013 Single-blind clinical trial Improvements of the motor and cognitive measures in PD patients Athauda et al., 2014…”
BackgroundEvaluation of neuroprotective effect of glucagon‐like peptide 1 analogs using neuroimaging
Femminella, G. D., & Edison, P. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.012 · Cited by 41
“[4] Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Ell P, Soderlund T, et al.”
InfluentialFrom metabolism to mind: The expanding role of the GLP-1 receptor in neurotherapeutics
Roy, A., Dawson, V. L., & Dawson, T. M. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00712 · Cited by 47
“Dual GLP-1/GIP agonists are in preclinical evaluation for synergistic neuro-protection; human trials are in planning stages [33,36,40,44,57 – 59].”
GLP-1: benefits beyond pancreas
Muscogiuri, G., Cignarelli, A., Giorgino, F., Prodram, F., Santi, D., Tirabassi, G., Balercia, G., Modica, R., Faggiano, A., & Colao, A. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0137-y · Cited by 42
“controls [43].”
Blood Pressure-Lowering Effects of Incretin-Based Diabetes Therapies
Lovshin, J. A., & Zinman, B. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.05.001 · Cited by 42
“Of those studied, it has been reported that GLP-1R agonists cross the blood-brain barrier (14,15) and some have been associated with neuroprotective effects in the central nervous system in different preclinical models of neurodegeneration (16), and more recently, in improving clinical performance scales in the settin…”
BackgroundLi, L., Zhang, L.-Y., Jin, Q.-Q., & Hölscher, C. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.303045 · Cited by 38
Cheng, Y.-H., Ho, M.-S., Huang, W.-T., Chou, Y.-T., & King, K. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.655662 · Cited by 38
“Both areas are anatomic sites of deficient functions in disease that are ameliorable by GLP-1 analog therapy, which improves memory/learning in an Alzheimer mouse model and Parkinson symptoms in humans (5, 6, 41).”
BackgroundPeptides as epigenetic modulators: therapeutic implications
Janssens, Y., Wynendaele, E., Berghe, W. V., & Spiegeleer, B. M. J. D. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0700-7 · Cited by 44
Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease
Liu, W., Li, Y., Jalewa, J., Saunders-Wood, T., Lin, L., & Hölscher, C. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.08.038 · Cited by 39
“Exendin-4 also has been tested in a pilot study in Parkinson's patients with promising first results (Aviles-Olmos et al., 2013, 2014).”
ResultParkinson’s disease: an update on pathogenesis and treatment
Foltynie, T., & Kahan, J. (2013) · Journal of Neurology · doi:10.1007/s00415-013-6915-1 · Cited by 40
Self-citationAntidiabetic Agents for Treatment of Parkinson’s Disease: A Meta-Analysis
Wang, S.-Y., Wu, S.-L., Chen, T.-C., & Chuang, C.-S. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17134805 · Cited by 37
Combined Diffusion Tensor Imaging and Arterial Spin Labeling as Markers of Early Parkinson’s disease
Wei, X., Yan, R., Chen, Z., Weng, R., Liu, X., Gao, H., Xu, X., Kang, Z., Liu, Z., Guo, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep33762 · Cited by 39
Birajdar, S. V., Mazahir, F., Alam, M. I., Kumar, A., & Yadav, A. K. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176117 · Cited by 42
Glucagon-like peptide 1 receptor activation: anti-inflammatory effects in the brain
Diz-Chaves, Y., Mastoor, Z., Spuch, C., Lamas, J. A., González-Matías, L. C., & Mallo, F. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.389626 · Cited by 46
Dei, A., Micheli, M. M., Aldigeri, R., Gardini, S., Pellegrini, F. F., Perini, M., Messa, G., Antonini, M., Spigoni, V., Cinquegrani, G., et al. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02320-7 · Cited by 47
“While proof-of-concept studies have supported beneficial effects of exenatide [14–17] in patients with Parkinson’s disease, data with GLP-1-RA in AD/MCI are scant and not conclusive [18–20] and mainly limited to a few pilot studies in the overt clinical and irreversible AD phase.”
BackgroundGlucagon-like peptide-1 receptor agonists for major neurocognitive disorders
Giorgi, R. D., Ghenciulescu, A., Yotter, C. N., Taquet, M., & Koychev, I. G. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2024-335593 · Cited by 48
“…the progress of 45 patients with moderate PD randomly assigned to exenatide or control and saw better scores (mean difference (MD) 4.9; 95% CI 0.3, 9.4) for the intervention group at 12 months as assessed by the Movement Disorders Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), 78”
InfluentialCarta, A. R., & Simuni, T. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.963195 · Cited by 36
“This evidence provides a rationale for evaluating established treatments for insulin resistance as possible disease-modifying drugs in PD, and antidiabetic drugs have been recently identified as possible neuroprotective agents in PD [39,40].”
BackgroundLeptin and ghrelin: Sewing metabolism onto neurodegeneration
de Candia, P., & Matarese, G. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.025 · Cited by 43
Novel Targets for Parkinson’s Disease: Addressing Different Therapeutic Paradigms and Conundrums
Rane, P., Sarmah, D., Bhute, S., Kaur, H., Goswami, A., Kalia, K., Borah, A., Dave, K. R., Sharma, N., & Bhattacharya, P. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00180 · Cited by 37
Network Analysis Identifies SOD2 mRNA as a Potential Biomarker for Parkinson's Disease
Santiago, J. A., Scherzer, C. R., & Potashkin, J. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109042 · Cited by 40
“Recently, drugs to treat diabetic patients, metformin-sulfonylurea and exenatide have shown promise in PD patients [52,53].”
BackgroundNew Therapeutics to Modulate Mitochondrial Function in Neurodegenerative Disorders
M. Wilkins, H., & K. Morris, J. (2017) · Current Pharmaceutical Design · doi:10.2174/1381612822666161230144517 · Cited by 35
Carroll, C., Webb, D., Stevens, K. N., Vickery, J., Eyre, V., Ball, S., Wyse, R. K. H., Webber, M., Foggo, A., Zajicek, J., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-029740 · Cited by 36
“25 Assuming that this increase in MDS-UPDRS part III is linear over time, gives an expected mean increase from baseline to 24 months of”
BackgroundSelf-citationWang, V., Kuo, T., Huang, E. Y., Ma, K., Chou, Y., Fu, Z.-Y., Lai, L.-W., Jung, J. H., Choi, H.-I., Choi, D., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00013 · Cited by 37
Bader, M., Li, Y., Lecca, D., Rubovitch, V., Tweedie, D., Glotfelty, E., Rachmany, L., Kim, H. K., Choi, H.-I., Hoffer, B. J., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.11.023 · Cited by 34
Neuroprotective Effects of Brain-Gut Peptides: A Potential Therapy for Parkinson’s Disease
Dong, D., Xie, J., & Wang, J. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-019-00407-3 · Cited by 38
“A small, proof-of-concept, open-label trial in which PD patients were treated with exenatide, a GLP-1 analogue, has shown that the motor and non-motor symptoms of the treated group improved more than the control group [29].”
BackgroundGLP-1 and the Degenerating Brain: Exploring Mechanistic Insights and Therapeutic Potential
Moaket, O. S., Obaid, S. E., Obaid, F. E., Shakeeb, Y. A., Elsharief, S. M., Tania, A., Darwish, R., Butler, A. E., & Moin, A. S. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110743 · Cited by 46
Arbo, B. D., Schimith, L. E., dos Santos, M. G., & Hort, M. A. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174800 · Cited by 34
Li, Y., Wu, K.-J., Yu, S.-J., Tamargo, I. A., Wang, Y., & Greig, N. H. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2016.11.010 · Cited by 33
Drug repurposing strategies of relevance for Parkinson’s disease
Fletcher, E. J. R., Kaminski, T. W., Williams, G. H., & Duty, S. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.841 · Cited by 32
Repackaging FDA-approved drugs for degenerative diseases: promises and challenges
Cummings, J. L., & Zhong, K. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.884923 · Cited by 33
“Minocycline and exenatide [13] are among repurposed agents with promise for the treatment of Parkinson’s disease.”
BackgroundNew animal models of Alzheimer’s disease that display insulin desensitization in the brain
Gao, C., Liu, Y., Li, L., & Hölscher, C. (2013) · Reviews in the Neurosciences · doi:10.1515/revneuro-2013-0034 · Cited by 31
“The drug has been shown to improve key motor control test outcomes as well as induce clear improvements in the Mattis cognitive scale for PD patients (Aviles-Olmos et al., 2013).”
BackgroundAbdelwahed, O. M., Tork, O. M., el Din, M. G., Rashed, L. A., & Zickri, M. B. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.02.002 · Cited by 37
Green, H., Tsitsi, P., Markaki, I., Aarsland, D., & Svenningsson, P. (2019) · CNS Drugs · doi:10.1007/s40263-018-0601-x · Cited by 33
Yang, Y., Ma, D., Xu, W., Chen, F., Du, T., Yue, W., Shao, S., & Yuan, G. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.10.005 · Cited by 32
“In addition, clinical trials with exenatide in Parkinson's disease (PD) suggest that exenatide can reduce PD symptoms, and that the motor and cognitive advantages persist at least a year after cessation of the exenatide treatment (Aviles-Olmos et al., 2013, 2014).”
BackgroundJanssens, J., Etienne, H., Idriss, S., Azmi, A., Martin, B., & Maudsley, S. R. (2014) · Frontiers in Endocrinology · doi:10.3389/fendo.2014.00142 · Cited by 32
Glucagon-Like Peptide 1 Receptor Agonists – Potential Game Changers in the Treatment of Glaucoma?
Mouhammad, Z. A., Vohra, R., Horwitz, A., Thein, A., Andreasen, J. R., Cvenkel, B., Williams, P. A., Azuara‐Blanco, A., & Kolko, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.824054 · Cited by 36
Immunomodulation and inflammation: Role of GLP-1R and GIPR expressing cells within the gut
Morrow, N. M., Morissette, A., & Mulvihill, E. E. (2024) · Peptides · doi:10.1016/j.peptides.2024.171200 · Cited by 34
Li, Y., Li, L., & Hölscher, C. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2016-0018 · Cited by 31
“…open-label pilot study by Aviles-Olmos et al. suggests that 12 months of treatment with exenatide improves motor and cognitive symptoms in PD patients (Aviles-Olmos et al., 2013a) and that the effect persists as long as 12 months after the termination of the treatment (Aviles-Olmos et al., 2014).”
BackgroundTherapies to Slow, Stop, or Reverse Parkinson’s Disease
Foltynie, T., & Langston, J. W. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181481 · Cited by 31
“There has been a lot of publicity surrounding the potential of Glucagon-like peptide 1 (GLP-1) receptor agonists in PD [24, 25].”
BackgroundSelf-citationMa, D., Liu, X., Liu, J., Li, M., Chen, L., Gao, M., Xu, W., & Yang, Y. (2019) · Brain Research · doi:10.1016/j.brainres.2019.02.030 · Cited by 33
Guttuso, T. J., Andrzejewski, K. L., Lichter, D. G., & Andersen, J. K. (2019) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2019.05.016 · Cited by 29
Li, Y., Glotfelty, E. J., Namdar, I., Tweedie, D., Olson, L., Hoffer, B. J., DiMarchi, R. D., Pick, C. G., & Greig, N. H. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113113 · Cited by 29
Research on developing drugs for Parkinson's disease
Zhang, C., Han, Q.-W., Chen, N., & Yuan, Y. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.12.017 · Cited by 29
Labandeira, C. M., Bau, A. F., Ron, D. A., Muñoz, A., Losada, G. A., Koukoulis, A., Romero-López, J., & Rodriguez-Perez, A. I. (2021) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2021.100914 · Cited by 28
Cognition and serotonin in Parkinson's disease
Frouni, I., Kwan, C., Belliveau, S., & Huot, P. (2022) · Progress in brain research · doi:10.1016/bs.pbr.2022.01.013 · Cited by 34
Mechanisms for the cardiovascular effects of glucagon-like peptide-1
Poudyal, H. (2015) · Acta Physiologica · doi:10.1111/apha.12604 · Cited by 34
“…satiety, energy expenditure, reward pathway modulation, neuroprotection, learning and stress (Larsen et al. 1997b, Rinaman, 1999, During et al. 2003, Bertilsson et al. 2008, Li et al. 2009, Martin et al. 2009, Gil-Lozano et al. 2010, McClean et al. 2011, Aviles-Olmos et al. 2013, Lockie, 2013).”
BackgroundZhang, P., Mao, C., Sun, A., Yang, Y., Hou, Y., Fu, Z., Tousi, B., Leverenz, J. B., Pieper, A. A., Luo, Y., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70639 · Cited by 33
The promise of GLP-1 receptor agonists for neurodegenerative diseases
Athauda, D. S., Greig, N. H., Meissner, W. G., Foltynie, T., & Gandhi, S. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194745 · Cited by 43
“Two early exenatide studies suggested motor and cognitive benefits that persisted beyond drug washout (154–156), accompanied by CSF detection of the drug and enhanced brain insulin signaling (157).”
Self-citationGLP‐1 improves neuropathology after murine cold lesion brain trauma
DellaValle, B., Hempel, C., Johansen, F. F., & Kurtzhals, J. A. L. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.99 · Cited by 27
Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience
Stott, S., Wyse, R. K. H., & Brundin, P. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.653377 · Cited by 32
“2 points in a parallel group of control patients who were on conventional PD treatment only (Aviles-Olmos et al., 2013).”
BackgroundSelf-citationLarsson, M., Lietzau, G., Nathanson, D., Östenson, C., Mallard, C. E., Johansson, M. E., Nyström, T., Patrone, C., & Darsalia, V. (2016) · Bioscience Reports · doi:10.1042/bsr20160437 · Cited by 29
Yu, S., Wang, Y., Shen, H., Bae, E.-K., Li, Y., Sambamurti, K., Tones, M. A., Zaleska, M. M., Hoffer, B. J., & Greig, N. H. (2024) · GeroScience · doi:10.1007/s11357-024-01116-0 · Cited by 28
GLP‐1 receptor agonists for Parkinson's disease: An updated meta-analysis
de Albuquerque, M. B., Nunes, L. E. D. B., Maldonado, J. V. D. O., Ferreira, D. G. M., Margato, M. M., Rabelo, L. V., Valênça, M. M., & Cordeiro, L. H. O. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.107220 · Cited by 30
Tseng, P., Zeng, B., Hsu, C.-W., Hung, C., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., Chen, J.-J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04018-w · Cited by 36
GLP-1, Parkinson’s Disease, and Neuroprotection
Standaert, D. G. (2024) · New England Journal of Medicine · doi:10.1056/nejme2401743 · Cited by 27
The retina-brain axis and diabetic retinopathy
Ebrahimi, M., Thompson, P. M., Lauer, A. K., Sivaprasad, S., & Perry, G. L. (2023) · European Journal of Ophthalmology · doi:10.1177/11206721231172229 · Cited by 27
Fessel, J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133729 · Cited by 30
“Administered to patients with Parkinson’s disease, cognition as reflected by the MDS-UPDRS scale, that only weakly reflects cognition, was increased in those receiving exenatide by 2.7 points and declined by 2.2 points in the control patients ( p = 0.037) [58].”
BackgroundInfluentialTakamatsu, Y., Ho, G. J., Koike, W., Sugama, S., Takenouchi, T., Waragai, M., Wei, J., Sekiyama, K., & Hashimoto, M. (2017) · npj Parkinson s Disease · doi:10.1038/s41531-016-0001-1 · Cited by 29
“Second, a number of studies have shown that diabetes-related vasculopathies, particularly atherosclerosis, may underlie the progression of neurodgeneration and clinical dementia.59 Indeed, vascular Aβ deposition manifesting as congophilic angiopathy is a consistent pathological feature in AD brain.60 Third, it has bee…”
BackgroundResultInfluentialZhang, Z., Li, H., Su, Y., Ma, J., Yuan, Y., Yu, Z., Shi, M., Shao, S., Zhang, Z., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.814430 · Cited by 31
Old wines in new bottles: Repurposing opportunities for Parkinson's disease
Kakkar, A. K., Singh, H., & Medhi, B. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.04.023 · Cited by 26
Hölscher, C. (2016) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000087 · Cited by 25
Zeissler, M., Li, V., Parmar, M., & Carroll, C. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-191856 · Cited by 27
Dysmetabolism and Neurodegeneration: Trick or Treat?
Capucho, A. M., Chegão, A., Martins, F. O., Miranda, H. V., & Conde, S. V. (2022) · Nutrients · doi:10.3390/nu14071425 · Cited by 29
Sandeep, X. X. X. X., Ahmad, M. H., Rani, L., & Mondal, A. C. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02867-7 · Cited by 25
“Clinical studies have shown that treatment with exenatide improves motor deficits and cognitive dysfunction in PD patients [141].”
BackgroundKopp, K. O., Li, Y., Glotfelty, E. J., Tweedie, D., & Greig, N. H. (2024) · Biomolecules · doi:10.3390/biom14070872 · Cited by 27
“…been completed, with encouraging results comprising improved off-medication motor scores, motor ability, and cognitive function in PD patients [40–43], as well as improved brain glucose metabolism [44] and reduced amyloid-β 1-42 concentration in neuronal-derived extracellular vesicles [45] in AD…”
ResultNew drug treatments show neuroprotective effects in Alzheimer′s and Parkinson′s diseases
Hölscher, C. (2014) · Neural Regeneration Research · doi:10.4103/1673-5374.145342 · Cited by 27
“Most interestingly, exendin-4 showed a clear improvement in the Mattis DRS-2 cognitive score, suggesting that exendin-4 has beneficial effects on cognition (Aviles-Olmos et al., 2013).”
Emerging preclinical pharmacological targets for Parkinson's disease
More, S. V., & Choi, D. (2016) · Oncotarget · doi:10.18632/oncotarget.8104 · Cited by 26
“Exenatide was found to improve motor and cognitive functions [175] over 12 months even though the drug was eliminated from the system [176].”
BackgroundMyeloid cells in retinal and brain degeneration
Guo, M., Schwartz, T. D., Dunaief, J. L., & Cui, Q. N. (2021) · FEBS Journal · doi:10.1111/febs.16177 · Cited by 27
Lin, Y., Hsu, C., Liu, J., Chang, K., & Huang, J. (2023) · Scientific Reports · doi:10.1038/s41598-023-49870-z · Cited by 24
“Two clinical trials have demonstrated that Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, improves both cognitive symptoms and motor deficits of PD patients 11,12 .”
BackgroundTargeting Glucose Metabolism: A Novel Therapeutic Approach for Parkinson’s Disease
Tanvir, A., Jo, J., & Park, S. M. (2024) · Cells · doi:10.3390/cells13221876 · Cited by 69
“Exenatide has shown promise in clinical trials for improving motor symptoms and potentially slowing PD progression [156].”
Treatment implications of the altered cytokine-insulin axis in neurodegenerative disease
Clark, I. A., & Vissel, B. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.07.030 · Cited by 23
Exendin-4 for Parkinson's disease
Esparza-Salazar, F. D. J., Lezama-Toledo, A. R., Rivera-Monroy, G., & Borlongan, C. V. (2021) · Brain Circulation · doi:10.4103/bc.bc_21_21 · Cited by 22
“[16] The second clinical trial involved a single‐blinded randomized study over a 12‐month period of self‐administered exenatide versus no treatment in 45 participants, who were subsequently monitored for 14 months and 24 months after 2 months and 12 months of exenatide cessation.[19] Performance bias was detected in o…”
BackgroundMethodType 2 diabetes mellitus/obesity drugs: A neurodegenerative disorders savior or a bridge too far?
Kopp, K. O., Glotfelty, E. J., Li, Y., Lahiri, D. K., & Greig, N. H. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102343 · Cited by 24
Basic science breaks through: New therapeutic advances in Parkinson's disease
Brundin, P., Atkin, G., & Lamberts, J. T. (2015) · Movement Disorders · doi:10.1002/mds.26332 · Cited by 26
The Emerging Role of GLP-1 Receptors in DNA Repair: Implications in Neurological Disorders
Yang, J., Chen, W., & Chen, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091861 · Cited by 25
“The first open-label clinical study reported that administration of exenatide, a long-acting GLP-1R agonist, showed long-lasting improvements in motor and cognitive function in PD patients [148].”
BackgroundThe Linked Clinical Trials initiative ( LCT ) for Parkinson's disease
Brundin, P., & Wyse, R. K. H. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.14175 · Cited by 23
Self-citationStructural Changes Observed in the Piriform Cortex in a Rat Model of Pre-motor Parkinson’s Disease
Sancandi, M., Schul, E. V., Economides, G., Constanti, A., & Mercer, A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00479 · Cited by 25
Hölscher, C. (2025) · CNS Drugs · doi:10.1007/s40263-025-01226-z · Cited by 30
Exendin‐4: A potential therapeutic strategy for Alzheimer's disease and Parkinson's disease
Verma, A., Chaudhary, S., Solanki, K., Goyal, A., & Yadav, H. N. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14426 · Cited by 24
“These patients were randomly divided into two groups: one group received exenatide for 12 months, with 20 patients completing the trial, while the other group, which served as the con-trol, consisted of 24 patients who also completed the trial (Aviles-Olmos et al., 2013).”
MethodThe Role of Intermittent Fasting in Parkinson's Disease
Neth, B. J., Bauer, B. A., Benarroch, E. E., & Savica, R. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.682184 · Cited by 24
“Glucagon-like peptide 1 (GLP-1) has been targeted through GLP-1 agonist, Exenatide, showing neuroprotective effects (34).”
BackgroundNoguchi, T., Katoh, H., Nomura, S., Okada, K., & Watanabe, M. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1342944 · Cited by 20
Faizan, M., Sarkar, A., & Singh, M. P. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101727 · Cited by 25
DeMaagd, G. A., & Philip, A. (2015) · Europe PMC (PubMed Central) · Cited by 33
Clinical Trial Highlights – GLP-1 agonists
McFarthing, K., Larson, D., & Simuni, T. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-200002 · Cited by 21
Bain, E. K., & Bain, S. C. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14487 · Cited by 20
Incretin-based therapeutics for the treatment of neurodegenerative diseases
Vear, A., Heneka, M. T., & Clemmensen, C. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01263-4 · Cited by 26
“The earliest trial found that 12 months of once-weekly treatment with exenatide resulted in clinically relevant functional improvements across motor and cognitive measures in people with moderate PD compared with healthy control individuals (NCT01174810) 162 .”
Targeting G Protein-Coupled Receptors in the Treatment of Parkinson’s Disease
Jones-Tabah, J. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167927 · Cited by 20
Targeting α-synuclein as a therapeutic strategy for Parkinson’s disease
Lawand, N., Saadé, N. E., El‐Agnaf, O. M. A., & Safieh‐Garabedian, B. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1062877 · Cited by 24
“It is now being investigated for therapeutic use in PD [89,90].”
Background
Metadata
- Authors
- Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., Limousin, P., & Foltynie, T.
- Affiliations
- University College London Hospitals NHS Foundation Trust (GB)
- UCL Queen Square Institute of Neurology (GB)
- UCL School of Pharmacy (GB)
- Cure Parkinson's Trust (GB)
- Corresponding author
- Foltynie, Thomas
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2013-05-20
- Volume
- 123
- Issue
- 6
- Pages
- 2730-2736
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3668846
- OpenAlex
- W2123319002
- Cited by
- 529
- References
- 25
- Citations by year
- 2026: 40 · 2025: 64 · 2024: 56 · 2023: 30 · 2022: 38 · 2021: 36 · 2020: 33 · 2019: 30 · 2018: 39 · 2017: 33 · 2016: 40 · 2015: 36 · 2014: 38 · 2013: 15
- FWCI
- 27.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- National Institute for Health and Care Research
- University College London Hospitals NHS Foundation Trust
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- exenatide, Parkinson's disease, drug repurposing, GLP-1 receptor agonists, neuroprotection, disease-modifying therapy, MDS-UPDRS, motor symptoms, cognitive function, non-motor symptoms, weight loss
- MeSH terms
- Exenatide, Aged, Antiparkinson Agents, Constipation, Female, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Middle Aged, Motor Activity, Parkinson Disease, Peptides, Venoms, Weight Loss, Disease Progression, Off-Label Use, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.